ES2175462T3 - Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos. - Google Patents

Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.

Info

Publication number
ES2175462T3
ES2175462T3 ES97942450T ES97942450T ES2175462T3 ES 2175462 T3 ES2175462 T3 ES 2175462T3 ES 97942450 T ES97942450 T ES 97942450T ES 97942450 T ES97942450 T ES 97942450T ES 2175462 T3 ES2175462 T3 ES 2175462T3
Authority
ES
Spain
Prior art keywords
hepatitis
virus
complex
crystals
ns4a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942450T
Other languages
English (en)
Inventor
Joseph L Kim
Kurt A Morgenstern
Chao Lin
Ted Fox
John A Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2175462T3 publication Critical patent/ES2175462T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES Y CRISTALES DEL VIRUS DE LA HEPATITIS C ASOCIADO CON SU COFACTOR VIRAL. LA INVENCION SE REFIERE ASIMISMO A PROCEDIMIENTOS DE UTILIZACION DE LOS COORDINADOS ESTRUCTURALES DE LA PROTEASA DEL VIRUS DE LA HEPATITIS C, FORMANDO COMPLEJO CON UN NS4A SINTETICO, PARA RESOLVER LOS PROBLEMAS RELACIONADOS CON LA ESTRUCTURA DE PROTEINAS O COMPLEJOS DE PROTEINAS SIMILARES U HOMOLOGAS.
ES97942450T 1996-09-12 1997-09-12 Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos. Expired - Lifetime ES2175462T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Publications (1)

Publication Number Publication Date
ES2175462T3 true ES2175462T3 (es) 2002-11-16

Family

ID=26699520

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01101009T Expired - Lifetime ES2202228T3 (es) 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c.
ES97942450T Expired - Lifetime ES2175462T3 (es) 1996-09-12 1997-09-12 Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01101009T Expired - Lifetime ES2202228T3 (es) 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c.

Country Status (12)

Country Link
US (2) US6153579A (es)
EP (1) EP0935609B1 (es)
JP (1) JP2001501602A (es)
AT (3) ATE244729T1 (es)
AU (1) AU736857B2 (es)
CA (1) CA2264964A1 (es)
DE (3) DE69712085T2 (es)
DK (1) DK0935609T3 (es)
ES (2) ES2202228T3 (es)
IL (1) IL128826A0 (es)
PT (2) PT1118619E (es)
WO (1) WO1998011134A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
IL143798A0 (en) 1999-01-08 2002-04-21 Bristol Myers Squibb Co Hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
CA2443393A1 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2009531315A (ja) * 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化ｃ型肝炎プロテアーゼインヒビター
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8575208B2 (en) 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
US6153579A (en) 2000-11-28
IL128826A0 (en) 2000-01-31
US6303287B1 (en) 2001-10-16
DK0935609T3 (da) 2002-07-22
ES2202228T3 (es) 2004-04-01
CA2264964A1 (en) 1998-03-19
DE69712085T2 (de) 2002-11-28
JP2001501602A (ja) 2001-02-06
AU4414597A (en) 1998-04-02
WO1998011134A1 (en) 1998-03-19
DE69736995D1 (de) 2007-01-04
DE69736995T2 (de) 2007-09-20
HK1038573A1 (en) 2002-03-22
EP0935609B1 (en) 2002-04-17
ATE216400T1 (de) 2002-05-15
DE69723485D1 (de) 2003-08-14
EP0935609A1 (en) 1999-08-18
AU736857B2 (en) 2001-08-02
ATE346088T1 (de) 2006-12-15
DE69712085D1 (de) 2002-05-23
HK1022700A1 (en) 2000-08-18
PT935609E (pt) 2002-09-30
ATE244729T1 (de) 2003-07-15
PT1118619E (pt) 2003-11-28
DE69723485T2 (de) 2004-05-27

Similar Documents

Publication Publication Date Title
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
EA199900388A1 (ru) Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
DK1066247T3 (da) Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
ITRM940092A0 (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
SV2003000617A (es) Inhibidores de la proteasa peptidomimetica ref. x-14912m
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
ATE380822T1 (de) Funf-helix protein
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE231557T1 (de) Detektion des hepatis-c virus.
NO308621B1 (no) Polynukleotider som er nyttige for screening av hepatitis C virus samt anvendelse av disse
DE69531235D1 (de) Säugetier - Expressionssysteme für Hüllenprotingene des Hepatitit - C - Virus
PE20020384A1 (es) PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
EP1802778A4 (en) HCV MULTIPLE EPITOPE FUSION ANTIGENS HAVING MODIFIED PROTEOLYTIC CLEAVAGE SITES AND USES THEREOF
ES2075149T3 (es) Copolimeros de anhidrido maleico.
ATE386122T1 (de) Neue gbv sequenz
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
ES2064071T3 (es) Antigeno viral de hepatitis delta, procedimiento para su purificacion y su utilizacion.
ES2130387T3 (es) Hcv peptidos y usos del mismo.
DK0642574T3 (da) Detergentsammensætninger
ES2177721T3 (es) Gonadotropinas con puentes disulforono nativos.
KR880008098A (ko) 광합성 시계

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 935609

Country of ref document: ES